Dr. Stacey Adam plays a leadership role at the FNIH, helping to lead many public-private partnerships, such as Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) the PPP that evaluated hundreds of available therapeutic agents with potential application for COVID-19, prioritized them, and designed and launched multiple master protocols to test them. Stacey oversees the Cancer, Metabolic Diseases, and Clinical COVID Research portfolios at the Foundation for the National Institute of Health (FNIH). Beyond ACTIV other major partnerships under her guidance include the two steering committees of the Biomarkers Consortium and their projects, Partnership for Accelerating Cancer Therapies (PACT), and the Lung Master Protocol (Lung-MAP) clinical trial. Prior to FNIH, she was a Manager at Deloitte Consulting within the Federal Life Sciences and Healthcare Strategy. She received her Ph.D. at Duke and postdoctoral training at Stanford.